These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19012507)

  • 1. Reovirus therapy in cancer: has the orphan virus found a home?
    Yap TA; Brunetto A; Pandha H; Harrington K; Debono JS
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1925-35. PubMed ID: 19012507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viral therapy using reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reovirus: Rationale and clinical trial update.
    Lal R; Harris D; Postel-Vinay S; de Bono J
    Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reovirus-based therapy for cancer.
    Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
    Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
    Stoeckel J; Hay JG
    Curr Opin Mol Ther; 2006 Jun; 8(3):249-60. PubMed ID: 16774045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
    Zhao X; Chester C; Rajasekaran N; He Z; Kohrt HE
    Mol Cancer Ther; 2016 May; 15(5):767-73. PubMed ID: 27197256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Viral Therapy Using Reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reovirus - possible therapy of cancer.
    Figova K; Hrabeta J; Eckschlager T
    Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
    Shmulevitz M; Marcato P; Lee PW
    Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.
    Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS
    Cytokine Growth Factor Rev; 2010; 21(2-3):91-8. PubMed ID: 20223697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
    Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
    BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.
    Bourhill T; Mori Y; Rancourt DE; Shmulevitz M; Johnston RN
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30103501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
    Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
    Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
    Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
    Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
    Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
    Shmulevitz M; Lee PW
    Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
    Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
    Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
    Hingorani P; Zhang W; Lin J; Liu L; Guha C; Kolb EA
    Cancer; 2011 Apr; 117(8):1764-74. PubMed ID: 21472724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncanonical Cell Death Induction by Reassortant Reovirus.
    Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.